{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-26-000098","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2026-10-16T11:48:00+00:00","discovered_at":"2026-10-16T11:50:00.762450+00:00","generated_at":"2026-10-16T11:50:04.941080+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Emergent BioSolutions CFO Richard Lindahl to retire Dec 31, 2026; Frank Vargo named interim CFO","bullets":["Richard S. Lindahl steps down as CFO and principal financial and accounting officer effective December 31, 2026, then serves as senior executive advisor through March 31, 2027 retirement.","Frank Vargo, 43, VP and Treasurer since November 2025, becomes interim CFO and principal financial and accounting officer starting January 1, 2027.","Vargo receives an additional $3,850 per pay period on top of his current $328,000 base salary, effective January 1, 2027; salary, bonus and equity remain commensurate with his prior seniority.","Lindahl will assist with the transition, including preparation and filing of the Form 10-K for the year ending December 31, 2026; his advisor pay is materially consistent with current compensation.","CEO Joe Papa thanked Lindahl for over eight years of service; the transition is tied to Emergent's multi-year transformation plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-26-000098","json":"https://secwatch.observer/filing/0001367644-26-000098.json","markdown":"https://secwatch.observer/filing/0001367644-26-000098.md","text":"https://secwatch.observer/filing/0001367644-26-000098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000098/0001367644-26-000098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000098/ebs-20261016.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-16T11:50:04.941080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04c75d4015","claim":"Richard Lindahl departed as Chief Financial Officer at Emergent BioSolutions Inc..","evidence_excerpt":"On October 16, 2026, Emergent BioSolutions Inc. (the “ Company ”) announced that Richard Lindahl, the Company’s Chief Financial Officer, will step down from his role as the Company’s principal financial and accounting officer effective December 31, 2026, after which he will continue as an advisor until his retirement on March 31, 2027.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000098/0001367644-26-000098-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"step down"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c4125258d6","claim":"Frank Vargo was appointed as Interim Chief Financial Officer at Emergent BioSolutions Inc..","evidence_excerpt":"The Company has appointed Frank Vargo, Vice President, Treasurer, to serve as the Company’s Interim Chief Financial Officer and principal financial and accounting officer beginning on January 1, 2027.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000098/0001367644-26-000098-index.htm","confidence":0.98,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}